Merrion Pharmaceuticals, Inc.
3013 Lake Drive
Citywest Business Campus
Dublin
24
Tel: +353-1-469-3719
Website: http://www.merrionpharma.com/
Email: info@merrionpharma.com
About Merrion Pharmaceuticals, Inc.
Merrion Pharmaceuticals is engaged in the development of oral forms (tablets/capsules) of drugs that have poor absorption and are generally given by injection.YEAR FOUNDED:
2003
LEADERSHIP:
Founder: Michael Donnelly
CEO: John Fox
CSO (Scientific): Thomas Leonard
19 articles about Merrion Pharmaceuticals, Inc.
-
Merrion Pharma Looks to Wind Up Operations, Announces Liquidation Plans
8/23/2016
-
Merrion Pharmaceuticals, Inc. Bids To Attract €52m Investment For Products
12/1/2014
-
Hovione And Merrion Pharmaceuticals, Inc. Announce Strategic Partnership On Use Of Merrion's GIPET Technology
7/15/2014
-
Merrion Pharmaceuticals, Inc. to Cut 20 Dublin Jobs
9/2/2011
-
Merrion Pharmaceuticals, Inc. and Novo Nordisk A/S Sign EUR 1.5M Deal for Oral Formulation Technology
12/22/2010
-
Merrion Pharmaceuticals, Inc. Signs Feasibility and Option Agreement for 3 Drugs With International 'Top Ten' Pharmaceutical Company
12/6/2010
-
Merrion Pharmaceuticals, Inc. Announces Commencement of Feasibility and Option Agreement With Rebel Pharmaceuticals
11/23/2010
-
Merrion Pharmaceuticals, Inc. Finalises Its Phase III Development Program for Orazol(TM) in the USA
11/16/2010
-
Merrion Pharmaceuticals, Inc. is Issued a Key U.S. Patent for Orazol(TM), Their Lead Product to Treat Bone Metastases Associated With Prostate, Breast and Other Cancers
5/7/2010
-
Merrion Pharmaceuticals, Inc. is Issued a Key United States Patent
3/2/2010
-
Novo Nordisk A/S Starts Phase 1 Trial With Oral Insulin Analogue -- Merrion Pharmaceuticals, Inc. Earns USD 2 Million Milestone Payment
12/7/2009
-
Merrion Pharmaceuticals, Inc. Announces Preliminary Results On Phase II Orazol(tm) Study
5/15/2009
-
Merrion Pharmaceuticals, Inc. Announces License Agreement With Novo Nordisk A/S to Develop Oral Formulation of GLP-1 Receptor Agonist(s) -- Novo Nordisk Makes Equity Investment in Merrion
1/16/2009
-
Merrion Pharmaceuticals, Inc. Receives 2008 Frost & Sullivan Osteoporosis Technology Innovation of the Year Award
11/5/2008
-
Merrion Pharmaceuticals, Inc. Announces Commencement of Next Stage of Oral Drug Research Collaboration Programme With Novo Nordisk A/S
7/18/2008
-
Merrion Pharmaceuticals, Inc. Cuts IPO Price Range to $6-$7 per ADS
10/30/2007
-
Merrion Pharmaceuticals, Inc. Sees IPO of 4 Million ADS at $10-$12 Each
9/4/2007
-
Merrion Pharmaceuticals, Inc. Announces Positive Clinical Results For Osteoporosis Drug MER 103
1/16/2007
-
Merrion Pharmaceuticals, Inc. Appoints Jonathan O'Connell As Chief Financial Officer
1/26/2006